MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease
MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease
Not yet recruiting · NCT07782021 · Registry updated 2026-08-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Not yet recruiting | Phase 4 | 2026-08-24 | NCT07782021 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eli Lilly and Company | 370 |
| Icahn School of Medicine at Mount Sinai | 256 |
| Washington University School of Medicine | 475 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |
| Washington University in St. Louis | Louis | United States | 1 |